Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 2666
  • Home
  • Print this page
  • Email this page
Year : 2011  |  Volume : 59  |  Issue : 3  |  Page : 248-251

Intravitreal bevacizumab (avastin) for circumscribed choroidal hemangioma

Department of Vitreoretina and Uvea Services, Dr. R. P. Center for Ophthalmic Sciences, AIIMS, New Delhi, India

Correspondence Address:
Prashant Naithani
Room No. 488, Fourth Floor, Dr. R. P. Center for Ophthalmic Sciences, AIIMS, Ansari Nagar, New Delhi - 10029
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0301-4738.81051

Rights and Permissions

Circumscribed choroidal hemangiomas are rare ophthalmic entities that cause diminution in vision due to accumulation of subretinal and/or intraretinal fluid in the macular area. Various treatment options ranging from conventional laser to photodynamic therapy have been employed to destroy the tumor and reduce the exudation; however, either the inability to penetrate through the exudative fluid or the collateral retinal damage induced by these treatment modalities make them unsuitable for lesions within the macula. We evaluated the role of intravitreal bevacizumab, a pan-vascular endothelial growth factor (VEGF) inhibitor, in reducing the sub- and intraretinal fluid in three patients with circumscribed choroidal hemangiomas. All the patients had complete resolution of the serous retinal detachment that was maintained till at least 12 months after the first injection. Intravitreal bevacizumab may be used in combination with thermal laser or photodynamic therapy in treating circumscribed choroidal hemangiomas with subretinal fluid.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded252    
    Comments [Add]    
    Cited by others 3    

Recommend this journal